Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.
Identifieur interne : 000057 ( Main/Exploration ); précédent : 000056; suivant : 000058Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.
Auteurs : Ivan Sanz Mu Oz [Espagne] ; Silvia Rojo Rello [Espagne] ; Raúl Ortiz De Lejarazu [Espagne]Source :
- Enfermedades infecciosas y microbiologia clinica [ 1578-1852 ] ; 2018.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (sang), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (prévention et contrôle), Humains (MeSH), Immunogénicité des vaccins (MeSH), Mâle (MeSH), Saisons (MeSH), Sujet âgé (MeSH), Tests d'inhibition de l'hémagglutination (MeSH), Vaccination (MeSH), Vaccins antigrippaux (immunologie), Virus influenza B (classification), Virus influenza B (immunologie).
- MESH :
- immunologie : Vaccins antigrippaux, Virus influenza B.
- prévention et contrôle : Grippe humaine.
- sang : Anticorps antiviraux, Virus influenza B.
- épidémiologie : Espagne.
- Femelle, Humains, Immunogénicité des vaccins, Mâle, Saisons, Sujet âgé, Tests d'inhibition de l'hémagglutination, Vaccination.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Aged (MeSH), Antibodies, Viral (blood), Female (MeSH), Hemagglutination Inhibition Tests (MeSH), Humans (MeSH), Immunogenicity, Vaccine (MeSH), Influenza B virus (classification), Influenza B virus (immunology), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Male (MeSH), Seasons (MeSH), Spain (epidemiology), Vaccination (MeSH).
- MESH :
- chemical , blood : Antibodies, Viral.
- geographic , epidemiology : Spain.
- classification : Influenza B virus.
- immunology : Influenza B virus, Influenza Vaccines.
- prevention & control : Influenza, Human.
- Aged, Female, Hemagglutination Inhibition Tests, Humans, Immunogenicity, Vaccine, Male, Seasons, Vaccination.
Abstract
INTRODUCTION
The aim of this study was to analyze the presence of antibodies against both Yamagata and Victoria influenza B lineages and to check the response after seasonal trivalent vaccination.
MATERIALS AND METHODS
Haemagglutination inhibition assays were performed with pre-and post-vaccination serum samples from 174 individuals ≥65 years of age vaccinated with seasonal trivalent influenza vaccines during the 2006-2007, 2008-2009, 2009-2010 and 2010-2011 vaccine campaigns.
RESULTS
33.9% of individuals showed pre-vaccine protective antibodies (≥1/40) against B/Yamagata lineage and 41.4% against B/Victoria lineage. The annual trivalent vaccine induced significant homologous seroconversion in 14-35.6% of individuals in each vaccine campaign.
CONCLUSIONS
The population ≥65 years has low-moderate seroprotection against B influenza lineages. Trivalent vaccination induced a slight increase of seroprotection. The trivalent vaccine should be administered to all individuals ≥65 years in all vaccine campaigns.
DOI: 10.1016/j.eimc.2017.10.021
PubMed: 29179984
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.</title><author><name sortKey="Mu Oz, Ivan Sanz" sort="Mu Oz, Ivan Sanz" uniqKey="Mu Oz I" first="Ivan Sanz" last="Mu Oz">Ivan Sanz Mu Oz</name><affiliation wicri:level="1"><nlm:affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. Electronic address: isanzm@saludcastillayleon.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid</wicri:regionArea><wicri:noRegion>Valladolid</wicri:noRegion></affiliation></author><author><name sortKey="Rello, Silvia Rojo" sort="Rello, Silvia Rojo" uniqKey="Rello S" first="Silvia Rojo" last="Rello">Silvia Rojo Rello</name><affiliation wicri:level="1"><nlm:affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid</wicri:regionArea><wicri:noRegion>Valladolid</wicri:noRegion></affiliation></author><author><name sortKey="Lejarazu, Raul Ortiz De" sort="Lejarazu, Raul Ortiz De" uniqKey="Lejarazu R" first="Raúl Ortiz De" last="Lejarazu">Raúl Ortiz De Lejarazu</name><affiliation wicri:level="1"><nlm:affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid</wicri:regionArea><wicri:noRegion>Valladolid</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29179984</idno><idno type="pmid">29179984</idno><idno type="doi">10.1016/j.eimc.2017.10.021</idno><idno type="wicri:Area/Main/Corpus">00080</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00080</idno><idno type="wicri:Area/Main/Curation">000080</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000080</idno><idno type="wicri:Area/Main/Exploration">000080</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.</title><author><name sortKey="Mu Oz, Ivan Sanz" sort="Mu Oz, Ivan Sanz" uniqKey="Mu Oz I" first="Ivan Sanz" last="Mu Oz">Ivan Sanz Mu Oz</name><affiliation wicri:level="1"><nlm:affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. Electronic address: isanzm@saludcastillayleon.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid</wicri:regionArea><wicri:noRegion>Valladolid</wicri:noRegion></affiliation></author><author><name sortKey="Rello, Silvia Rojo" sort="Rello, Silvia Rojo" uniqKey="Rello S" first="Silvia Rojo" last="Rello">Silvia Rojo Rello</name><affiliation wicri:level="1"><nlm:affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid</wicri:regionArea><wicri:noRegion>Valladolid</wicri:noRegion></affiliation></author><author><name sortKey="Lejarazu, Raul Ortiz De" sort="Lejarazu, Raul Ortiz De" uniqKey="Lejarazu R" first="Raúl Ortiz De" last="Lejarazu">Raúl Ortiz De Lejarazu</name><affiliation wicri:level="1"><nlm:affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid</wicri:regionArea><wicri:noRegion>Valladolid</wicri:noRegion></affiliation></author></analytic><series><title level="j">Enfermedades infecciosas y microbiologia clinica</title><idno type="eISSN">1578-1852</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Antibodies, Viral (blood)</term><term>Female (MeSH)</term><term>Hemagglutination Inhibition Tests (MeSH)</term><term>Humans (MeSH)</term><term>Immunogenicity, Vaccine (MeSH)</term><term>Influenza B virus (classification)</term><term>Influenza B virus (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Seasons (MeSH)</term><term>Spain (epidemiology)</term><term>Vaccination (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (sang)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Immunogénicité des vaccins (MeSH)</term><term>Mâle (MeSH)</term><term>Saisons (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Tests d'inhibition de l'hémagglutination (MeSH)</term><term>Vaccination (MeSH)</term><term>Vaccins antigrippaux (immunologie)</term><term>Virus influenza B (classification)</term><term>Virus influenza B (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza B virus</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Male</term><term>Seasons</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Immunogénicité des vaccins</term><term>Mâle</term><term>Saisons</term><term>Sujet âgé</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>The aim of this study was to analyze the presence of antibodies against both Yamagata and Victoria influenza B lineages and to check the response after seasonal trivalent vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>Haemagglutination inhibition assays were performed with pre-and post-vaccination serum samples from 174 individuals ≥65 years of age vaccinated with seasonal trivalent influenza vaccines during the 2006-2007, 2008-2009, 2009-2010 and 2010-2011 vaccine campaigns.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>33.9% of individuals showed pre-vaccine protective antibodies (≥1/40) against B/Yamagata lineage and 41.4% against B/Victoria lineage. The annual trivalent vaccine induced significant homologous seroconversion in 14-35.6% of individuals in each vaccine campaign.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The population ≥65 years has low-moderate seroprotection against B influenza lineages. Trivalent vaccination induced a slight increase of seroprotection. The trivalent vaccine should be administered to all individuals ≥65 years in all vaccine campaigns.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29179984</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1852</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>11</Month></PubDate></JournalIssue><Title>Enfermedades infecciosas y microbiologia clinica</Title><ISOAbbreviation>Enferm. Infecc. Microbiol. Clin.</ISOAbbreviation></Journal><ArticleTitle>Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.</ArticleTitle><Pagination><MedlinePgn>572-575</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0213-005X(17)30321-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eimc.2017.10.021</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The aim of this study was to analyze the presence of antibodies against both Yamagata and Victoria influenza B lineages and to check the response after seasonal trivalent vaccination.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Haemagglutination inhibition assays were performed with pre-and post-vaccination serum samples from 174 individuals ≥65 years of age vaccinated with seasonal trivalent influenza vaccines during the 2006-2007, 2008-2009, 2009-2010 and 2010-2011 vaccine campaigns.</AbstractText><AbstractText Label="RESULTS">33.9% of individuals showed pre-vaccine protective antibodies (≥1/40) against B/Yamagata lineage and 41.4% against B/Victoria lineage. The annual trivalent vaccine induced significant homologous seroconversion in 14-35.6% of individuals in each vaccine campaign.</AbstractText><AbstractText Label="CONCLUSIONS">The population ≥65 years has low-moderate seroprotection against B influenza lineages. Trivalent vaccination induced a slight increase of seroprotection. The trivalent vaccine should be administered to all individuals ≥65 years in all vaccine campaigns.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muñoz</LastName><ForeName>Ivan Sanz</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. Electronic address: isanzm@saludcastillayleon.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rello</LastName><ForeName>Silvia Rojo</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lejarazu</LastName><ForeName>Raúl Ortiz de</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Valladolid National Influenza Centre, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Microbiology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Enferm Infecc Microbiol Clin</MedlineTA><NlmUniqueID>9104081</NlmUniqueID><ISSNLinking>0213-005X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antibodies</Keyword><Keyword MajorTopicYN="Y">Anticuerpos</Keyword><Keyword MajorTopicYN="Y">Influenza B lineages</Keyword><Keyword MajorTopicYN="Y">Linajes de gripe B</Keyword><Keyword MajorTopicYN="Y">Trivalent influenza vaccination</Keyword><Keyword MajorTopicYN="Y">Vacuna trivalente de gripe</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29179984</ArticleId><ArticleId IdType="pii">S0213-005X(17)30321-X</ArticleId><ArticleId IdType="doi">10.1016/j.eimc.2017.10.021</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Mu Oz, Ivan Sanz" sort="Mu Oz, Ivan Sanz" uniqKey="Mu Oz I" first="Ivan Sanz" last="Mu Oz">Ivan Sanz Mu Oz</name></noRegion><name sortKey="Lejarazu, Raul Ortiz De" sort="Lejarazu, Raul Ortiz De" uniqKey="Lejarazu R" first="Raúl Ortiz De" last="Lejarazu">Raúl Ortiz De Lejarazu</name><name sortKey="Rello, Silvia Rojo" sort="Rello, Silvia Rojo" uniqKey="Rello S" first="Silvia Rojo" last="Rello">Silvia Rojo Rello</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000057 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000057 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29179984
|texte= Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29179984" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |